Igoris Trociukas

Vilnius University Hospital Santariskiu Klinikos

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Laimonas Griškevičius

Vilnius University Hospital Santariskiu Klinikos

AŽ

Andrius Žučenka

Vilnius University

Regina Pileckytė

National Research Center for Hematology Russian Academy of Medical Sciences

Vilmantė Vaitekėnaitė

Vilnius University

Guoda Daukėlaitė

Vilnius University

Linas Davainis

Vilnius University Hospital Santariskiu Klinikos

Dominika Vasilevska

Vilnius University

Valdas Pečeliūnas

Vilnius University

Lukas Kevličius

Vilnius University

RČ

Rūta Čepulytė

The University of Texas Health Science Center at Houston

Cooperative Institutions

Merck & Co., Inc., Rahway, NJ, USA (United States)

Vilnius University

Vilnius University Hospital Santariskiu Klinikos

Cornell University

Stanford University

Tel Aviv University

The University of Texas MD Anderson Cancer Center

Istituti di Ricovero e Cura a Carattere Scientifico

University of Chicago

Weill Cornell Medicine

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Venetoclax-Based Therapies for Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 in Clinical Practice Setting

Blood (2022)

Andrius Žučenka Lukas Kevličius Linas Davainis Birutė Davainienė Kazimieras Maneikis

Venetoclax

Azacitidine

Decitabine

10.1182/blood-2022-165459

Cite

Citations (0)

POSTER: AML-519 Sequential Allogeneic Stem Cell Transplantation (alloSCT) After Venetoclax (Ven)-Based Therapy for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Myelodysplastic Syndrome With Excess Blasts 2 (MDS-EB2)

Clinical Lymphoma Myeloma & Leukemia (2023)

Dominika Vasilevska Guoda Daukėlaitė Igoris Trociukas Regina Pileckytė Laimonas Griškevičius

Venetoclax

Ven

Refractory (planetary science)

Azacitidine

Salvage therapy

10.1016/s2152-2650(23)00469-x

Cite

Citations (0)

[Chronic graft-versus-host disease presenting as nephrotic syndrome after allogenic hematopoietic stem cell transplantation].

PubMed (2007)

Janina Priluckienė Indre Kriukelyte Mindaugas Jurgutis Igoris Trociukas

Complications of allogenic hematopoietic stem cell transplantation that occur in the first 100 days are considered early and those that begin 100 days after are considered late complications. Chronic graft-versus-host disease is the most common late complication of allogenic hematopoietic cell transplantation, which occurs in 60-80% of long-term survivors and causes significant morbidity and mortality. It is well known that it affects primarily the skin, mucous membranes, cells in the gastrointestinal tract and liver. The kidneys are not considered a target organ for chronic graft-versus-host disease in humans, although renal involvement in patients with chronic graft-versus-host disease, presenting as nephrotic syndrome, has been reported in patients who underwent allogenic transplantation. We present a case of chronic graft-versus-host disease that manifested as nephrotic syndrome after hematopoietic cell transplantation performed 3 years ago. Kidney biopsy revealed membrane nephropathy. Treatment with cyclosporine and methylprednisolone significantly reduced albuminuria.

Source

Cite

Citations (0)

N92 Sequential high-dose chemotherapy with hematopoietic stem-cell support in poor risk, relapsed or refractory germ-cell tumor patient treatment: Lithuanian experience

European Urology Supplements (2009)

J. Korsakas K. Andrekute-Aleksiejiene Adomas Bukauskas Birutė Brasiūnienė Igoris Trociukas

Refractory (planetary science)

Salvage therapy

10.1016/s1569-9056(09)74866-3

Cite

Citations (0)

Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation